Literature DB >> 11777327

Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes.

T Nakamura, C Ushiyama, S Osada, N Shimada, I Ebihara, H Koide.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11777327

Source DB:  PubMed          Journal:  Ren Fail        ISSN： 0886-022X            Impact factor:   2.606


× No keyword cloud information.
  3 in total

1.  Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes.

Authors:  Steven M Brunelli; Ravi Thadhani; T Alp Ikizler; Harold I Feldman
Journal:  Kidney Int       Date:  2009-02-04       Impact factor: 10.612

2.  Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006-2016.

Authors:  Min-Hao Lin; Huang-Yu Yang; Chieh-Li Yen; Chao-Yi Wu; Chang-Chyi Jenq; George Kuo; Wei-Sheng Peng; Jia-Rou Liu; Ya-Chung Tian; Chih-Wei Yang; Gerard F Anderson; Lai-Chu See
Journal:  J Clin Med       Date:  2020-11-06       Impact factor: 4.241

Review 3.  Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

Authors:  Clement Lo; Tadashi Toyama; Ying Wang; Jin Lin; Yoichiro Hirakawa; Min Jun; Alan Cass; Carmel M Hawley; Helen Pilmore; Sunil V Badve; Vlado Perkovic; Sophia Zoungas
Journal:  Cochrane Database Syst Rev       Date:  2018-09-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.